Stock Performance and Market Context
On 28 April 2026, Fredun Pharmaceuticals Ltd recorded a remarkable day change of 6.71%, substantially outperforming the Sensex, which posted a modest gain of 0.15%. The stock opened with a gap up of 2.81% and reached an intraday high of Rs 2,145, marking a 5.19% increase during the trading session. This surge places the stock comfortably above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling a strong bullish trend.
Over various time horizons, Fredun Pharmaceuticals has demonstrated exceptional performance relative to the broader market. The one-month return stands at 28.48%, compared to the Sensex’s 5.22%. Over three months, the stock surged 44.84%, while the Sensex declined by 5.98%. The one-year performance is particularly striking, with a gain of 209.87% against the Sensex’s negative 3.49%. Year-to-date, the stock has appreciated by 37.87%, contrasting with the Sensex’s 9.15% decline. Even over longer periods, Fredun Pharmaceuticals has outpaced the market, delivering 139.48% returns over three years and an extraordinary 428.30% over five years, dwarfing the Sensex’s respective 26.69% and 55.67% gains. The ten-year return is exceptional at 15,679.91%, compared to the Sensex’s 202.39%.
Financial Growth and Profitability Metrics
The company’s robust stock performance is underpinned by strong financial fundamentals. Fredun Pharmaceuticals has achieved a healthy compound annual growth rate (CAGR) in net sales of 38.09% over five years, accompanied by an impressive operating profit growth of 58.31% during the same period. The latest quarterly results, declared in December 2025, were very positive, with operating profit increasing by 99.09%.
Key quarterly figures include a Profit Before Tax (PBT) excluding other income of Rs 14.00 crores, growing at 96.35%, and a Profit After Tax (PAT) of Rs 10.48 crores, up 96.6%. Net sales for the quarter stood at Rs 160.93 crores, reflecting a 56.70% increase. The company has reported positive results for seven consecutive quarters, underscoring consistent operational strength.
Return on Capital Employed (ROCE) is reported at 20.2%, indicating efficient utilisation of capital. The enterprise value to capital employed ratio is 4.02x, suggesting a fair valuation relative to the company’s capital base. The Price/Earnings (P/E) ratio stands at 34x, with a Price to Book Value (P/BV) of 7.13x. The PEG ratio of 0.61x indicates that the stock’s price growth is reasonably aligned with its earnings growth, supporting the valuation’s sustainability.
Promoter Confidence and Shareholding
Promoter confidence in Fredun Pharmaceuticals remains strong, with promoters increasing their stake by 1.11% over the previous quarter to hold 44.17% of the company’s equity. This rise in promoter shareholding is a positive indicator of their commitment to the company’s growth trajectory and long-term prospects.
Technical Analysis and Market Sentiment
The technical outlook for Fredun Pharmaceuticals is bullish. The current trend shifted to bullish on 9 April 2026 at a price level of Rs 1,830, moving from a mildly bullish stance. Weekly and monthly technical indicators such as MACD and KST are bullish, while Bollinger Bands show mild to full bullish signals. The stock’s immediate support is at Rs 635.05, the 52-week low, with resistance levels at Rs 1,856.12 (20-day moving average), Rs 1,688.83 (100-day moving average), and Rs 1,496.94 (200-day moving average). The 52-week high was Rs 1,999.00, which the stock has now surpassed, confirming the new all-time high.
Delivery volumes have also shown strength, with a 1-month delivery change of 43.57% and a 1-day delivery change of 51.44% compared to the 5-day average, indicating increased investor participation in recent trading sessions.
Valuation and Dividend Profile
Fredun Pharmaceuticals is classified as a micro-cap company with a market capitalisation grade reflecting this status. The stock trades at an EV/EBITDA multiple of 15.47x and EV/EBIT of 16.69x, with an EV/Sales ratio of 2.17x. Dividend yield remains modest at 0.03%, with the latest dividend declared at Rs 0.7 per share and a payout ratio of 2.11%. The ex-dividend date was 23 September 2025.
Quality Assessment and Financial Health
The company’s overall quality grade is average, based on long-term financial performance. While growth metrics are excellent, with a 5-year sales growth of 38.09% and EBIT growth of 58.31%, capital structure and leverage indicators are less robust. The average EBIT to interest coverage ratio is 2.58x, indicating moderate ability to service debt, and the average net debt to equity ratio is 1.03, reflecting relatively high leverage. Institutional holdings are low at 3.89%, and there is no promoter share pledging.
Tax ratio stands at 22.75%, and dividend payout remains low, consistent with the company’s focus on reinvestment and growth. Return on equity (ROE) and ROCE are modest at 13.09% and 14.74%, respectively, suggesting room for improvement in capital efficiency.
Summary of the Journey to the All-Time High
Fredun Pharmaceuticals Ltd’s ascent to an all-time high price of Rs 2,176.05 is the culmination of sustained financial growth, strong quarterly results, and positive market sentiment. The stock’s performance has consistently outpaced benchmark indices such as the Sensex and BSE500 across multiple time frames, reflecting the company’s ability to deliver value to shareholders. Promoter confidence, as evidenced by increased stakeholding, and a bullish technical outlook further reinforce the stock’s strong position in the Pharmaceuticals & Biotechnology sector.
This milestone highlights the company’s successful execution of its growth strategy, underpinned by expanding sales, improving profitability, and disciplined capital management. While valuation multiples suggest a premium relative to some peers, the company’s earnings growth and operational metrics provide a solid foundation for the current market valuation.
